Neotame is an artificial high-intensity sweetener derived from aspartame — thousands of times sweeter than sugar, with effectively no calories and almost no effect on blood sugar. It is FDA-approved, but it is named in the WHO's 2023 non-sugar-sweetener advisory, and recent laboratory research has raised questions about its effect on the gut.
Neotame is an artificial sweetener developed from aspartame, modified so that it is far sweeter and more stable. It is roughly 7,000 to 13,000 times sweeter than sugar — so intensely sweet that only trace amounts are used — and contributes effectively no calories. It was approved by the US Food and Drug Administration as a general-purpose sweetener in 2002.
Unlike aspartame, neotame does not require a phenylketonuria (PKU) warning, because the amounts used are so small that the phenylalanine released is negligible. Like other high-intensity sweeteners, neotame provides sweetness only: it is not a sugar and does not brown, caramelize, add bulk or hold moisture. It appears in some diet beverages, tabletop blends and processed foods, though it is less common than sucralose or aspartame.
Neotame is rapidly metabolized and largely excreted, and because so little is used it contributes effectively no calories and does not meaningfully raise blood glucose. It is more heat-stable than aspartame, which allows limited use in baked goods.
For most of its approved life, neotame was treated as inert at the tiny amounts used. Newer laboratory research has begun to examine whether it affects the gut — see the safety section below.
Neotame is approved and has been used for two decades. The honest picture has three parts: the regulatory position, the WHO advisory, and the newer gut research.
Neotame is FDA-approved as a general-purpose sweetener and is permitted in the US, the EU and many other countries.
The FDA approved neotame in 2002, and the European Food Safety Authority has assessed it and set an acceptable daily intake. For ordinary use, regulators continue to permit it.
The WHO advises against using non-sugar sweeteners — neotame among the examples it named — for weight control or to reduce disease risk in the general population.
In 2023 the WHO recommended that the general population not use non-sugar sweeteners to manage weight or lower chronic-disease risk, and named neotame among the examples. The recommendation rests on observational associations the WHO graded as low certainty — a precautionary position, not a finding that neotame causes those outcomes. Allulose and the low-calorie sugars are not covered by the advisory.
A 2024 laboratory gut model reported that neotame damaged intestinal-lining cells and altered gut bacteria — an early lab finding, not a regulatory reversal.
In 2024, a laboratory study using a gut model (Caco-2 intestinal cells with model gut bacteria) reported that neotame could damage the cells lining the intestine and push otherwise healthy gut bacteria toward harmful behavior (Frontiers in Nutrition). This is in-vitro work — it points to a mechanism worth studying, not a demonstration of harm at normal intakes in people. Direct human trials of neotame are limited; for balance, a 2024 randomized crossover trial from the industry-linked SWEET consortium found that replacing sugar with neotame did not increase appetite and modestly lowered post-meal glucose and insulin (eBioMedicine). As with all non-sugar sweeteners, the WHO nonetheless advises against relying on it for weight control.
Neotame remains FDA-approved, calorie-free and effective as a sweetener at tiny doses, and unlike aspartame it carries no PKU warning. At the same time it is named in the WHO's 2023 advisory, and the 2024 laboratory gut research is a real signal that deserves follow-up rather than dismissal — or, equally, rather than alarm.
The accurate summary: an approved, very-high-intensity artificial sweetener that the WHO advises the general population not to rely on for weight or disease-risk reasons, with early laboratory questions about gut effects and no demonstrated weight benefit. Like all high-intensity sweeteners, it provides sweetness only and none of sugar's functional roles.
US federal guidance advises limiting non-nutritive sweeteners generally.
The 2025–2030 Dietary Guidelines for Americans state that "no amount of added sugars or non-nutritive sweeteners is recommended or considered part of a healthy or nutritious diet," and list neotame among non-nutritive sweeteners. This is not a consumer ban, but it reflects a clear direction of official caution toward the category.
The two are very different kinds of ingredient; the contrast shows what each can and cannot do.
| Property | Neotame | Allulose |
|---|---|---|
| Type of ingredient | Artificial high-intensity sweetener | Rare sugar (monosaccharide) |
| Is it a sugar? | No | Yes |
| Calories per gram | Effectively zero | ~0.4 |
| Glycemic index | Negligible | Zero |
| Browns & caramelizes | No | Yes |
| Provides bulk / structure | No | Yes |
| Covered by WHO 2023 advisory | Yes | No |
| Open research questions | 2024 gut-model research | No comparable question raised |
| US regulatory status | FDA-approved | GRAS |
Allulose is a sugar and behaves like one — it browns, caramelizes, adds bulk and holds moisture, none of which neotame can do. Allulose sits outside the WHO's 2023 advisory and is not the subject of the 2024 gut-model questions raised about neotame. Those are the substantive distinctions for a reader weighing the two.
Neotame is FDA-approved and calorie-free. It is named in the WHO's 2023 advisory against relying on non-sugar sweeteners, a precautionary position based on observational associations. Recent 2024 laboratory research raised questions about effects on the gut lining and bacteria; that is early, lab-based work, not a finding of harm at normal intakes in people.
Neotame is derived from aspartame but chemically modified to be far sweeter and more stable. Because so little is used, it does not require the PKU warning that aspartame carries.
No. Neotame has a negligible effect on blood glucose because it is used in trace amounts and is not metabolized for energy in a way that raises blood sugar.
Yes. The FDA approved neotame as a general-purpose sweetener in 2002, and the European Food Safety Authority has also assessed it.
The WHO advises against relying on non-sugar sweeteners, including neotame, for weight control. Direct trials are limited; a 2024 randomized trial found that replacing sugar with neotame did not increase appetite and modestly lowered post-meal glucose and insulin, but it did not establish a weight-loss benefit. The honest position: it is a zero-calorie way to sweeten, not a proven weight-loss tool.
See how neotame and the other sweeteners line up on calories, glycemic impact, baking behavior and the WHO advisory — all side by side.
Open the comparison hub →